Schizophrenia

West Virginia

12 Schizophrenia Trials near West Virginia

Power is an online platform that helps thousands of Schizophrenia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

OLZ/SAM for Schizophrenia

West Chester, Ohio
This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:10 - 17

236 Participants Needed

In this study, the investigators will examine whether a deprescription of unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can augment quality of life, functioning, and neurocognition in individuals who with schizophrenia. Individuals identified by clinical services who have unneeded prescriptions benztropine or trihexyphenidyl will be eligible for deprescription and study entry. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will will be randomized to either staying on their anticholinergic drugs or undergoing deprescription per routine clinical care, and will undergo follow-up evaluations across 6 months. The investigators predict that reducing and deprescribing these drug, if clinically determined to be unnecessary will will enhance functioning, neurocognition
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:40 - 70

105 Participants Needed

This is a multicenter open-label, pilot study to evaluate the safety and tolerability of bromocriptine, a dopamine D2/D3 receptor and serotonin 5-HT2C receptor agonist, as an adjunct to preexisting standard-of-care antipsychotic drug (APD) regimens in the management of APD-associated impaired glucose tolerance (IGT)/insulin resistance (IR). The ultimate aim of the study team is to evaluate the efficacy of bromocriptine in treating the metabolic disturbances associated with APDs and the hypothesis is that bromocriptine will be a well-tolerated, safe, and inexpensive way to ameliorate these metabolic complications and prevent or delay the onset of type 2 diabetes (T2D). This study will be a small, short-duration pilot focusing on safety and tolerability. A total of 15 psychiatrically stable APD-treated adult outpatients, VA Pittsburgh , aged 18 to 65 years old, with a confirmed diagnosis of schizophrenia and comorbid IGT will be recruited and receive 6 weeks of bromocriptine (flexibly titrated, 2.5-5.0 mg PO daily). Key inclusion criteria are: 1) currently being treated with second generation APDs for 3 or more months with no change in dose in the 1 month prior to enrollment, 2) fasting glucose 100 to 125mg/dL and/or hemoglobin A1c (HbA1c) 5.7-6.4%. Key exclusions are: 1) prior APD nonadherence, 2) drug/alcohol abuse in the 3 months prior to screening, 3) a history of violent behavior/psychoses, 4) pregnancy, or 5) a diagnosis of diabetes. Subjects on other dopamine agonists or on medications that may interact with bromocriptine and those taking corticosteroids or other medications that may alter glucose levels will be excluded. The purposes of the study are to demonstrate safety/tolerability, demonstrate feasibility, provide proof of concept, and provide an open-label assessment of the metabolic and psychiatric effects of bromocriptine in patients with schizophrenia treated with APDs. The primary metabolic outcome measures will be change in IR as measured by the HOMA-IR and change in IGT measured by HbA1c. Secondary metabolic outcome measures include body weight, fasting lipids, and prolactin. The specific aims are as follows: Specific aim 1: To establish the safety and tolerability of bromocriptine in patients with schizophrenia and IGT/IR treated with APDs. Specific aim 2: To demonstrate feasibility/proof of concept for an improvement in APD-induced IGT/IR with bromocriptine.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 4

15 Participants Needed

Acetazolamide for Schizophrenia

Pittsburgh, Pennsylvania
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Stay on current meds

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 55

60 Participants Needed

Cromoglicate for Schizophrenia

Pittsburgh, Pennsylvania
This trial tests a drug used for asthma and allergies on schizophrenia patients who don't fully respond to standard treatments. The drug may help by protecting the brain and targeting specific brain proteins. The drug has been used for years in treating asthma and allergies, showing effectiveness in stabilizing certain cells in the body and reducing the need for other medications.
Stay on current meds

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65

160 Participants Needed

In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive treatment with clozapine. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will undergo a session of iTBS +MRI and session of sham delivery + MRI. The order for these sessions will be blinded and randomized. The investigators predict that accelerated iTBS will enhance neurocognition relative to sham delivery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 50

30 Participants Needed

This trial investigates if playing sounds during deep sleep can improve sleep and memory in people with early-course schizophrenia. The study aims to see if enhancing specific brain activities during sleep helps with cognitive functions.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 40

200 Participants Needed

This is a hybrid1, effectiveness-implementation study of yoga-based exercises (YE) as an adjunctive tool for rehabilitation among persons with Severe Mental Illness (SMI). The two-arm randomized controlled trial will compare the efficacy of YE compared to the Wellness Lifestyle Program (WLP). Primary outcomes of the study will be self-report and performance-based measures of community functioning, defined in the investigators study as social, leisure, employment, and life skills functioning in the community. Secondary outcomes will include cognition and physical fitness measures.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

112 Participants Needed

This trial will test if a special type of brain stimulation called iTBS can improve brain activity and memory in people with early-stage schizophrenia. The treatment uses magnetic pulses to boost brain rhythms in a specific area linked to memory. Researchers will compare the effects of different treatments to see if iTBS makes a difference. Intermittent theta burst stimulation (iTBS) is a noninvasive brain stimulation technique that has shown promise in treating various psychiatric and neurological conditions, including treatment-resistant depression and cognitive impairments.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 40

75 Participants Needed

This project will conduct a confirmatory efficacy trial of two novel psychosocial interventions, Cognitive Enhancement Therapy and Enriched Supportive Therapy, for the treatment of persistent negative symptoms in schizophrenia.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60

90 Participants Needed

This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:5 - 17

310 Participants Needed

The Veterans Health Administration (VHA) is advocating that Veterans with serious mental illness (SMI) receive recovery-oriented, rehabilitation approaches that target real-world functioning. One such approach is Cognitive-Behavioral Social Skills Training (CBSST). Unlike traditional cognitive-behavioral therapy, CBSST is a more recovery-oriented psychosocial rehabilitation intervention that teaches Veterans with SMI to correct errors in thinking and build social skills. While effective, CBSST has only been tested when facilitated by masters- or doctoral-level therapists, which limits its use in VHA. However, the investigators' pilot data shows that Peer Specialists-individuals with SMI who are hired and trained to use their own recovery experience to assist others with SMI-can also provide CBSST (called CBSST-Peer). Stand-alone social skills training (SST) is also a recovery-oriented program that VHA is attempting to rollout nationwide for Veterans with SMI. A few Peer Specialists have been trained to co-lead SST with professionals. However, SST is not widely implemented because professionals are busy and Peer Specialist delivered SST has not been tested. This study will evaluate the effectiveness of Peer Specialist-delivered CBSST and SST, which would increase access Veterans with SMI have to effective treatment. The investigators' aims are: Aim 1 (Effectiveness): To compare the impact of CBSST-Peer on outcomes in Veterans with SMI to Veterans receiving Peer Specialist-delivered SST groups of equal duration and to treatment as usual. The investigators will also assess fidelity of SST and CBSST. Aim 2: (Helpfulness of CBSST/SST--Peer and implementation barriers and facilitators): To use focus groups with patients and interviews with Peer Specialists and other staff to assess perceptions of SST- and CBSS Peer and identify potential barriers and facilitators to future implementation. Methods: This is a randomized, Hybrid 1 trial involving 252 Veterans with SMI (n=126 each from Pittsburgh, San Diego) comparing 3 treatment arms: CBSST-Peer vs. SST-Peer vs. treatment as usual. Hybrid 1 trials test the effectiveness of an intervention and collect implementation data that could inform its future adoption. At each site, across 6 waves (a wave = 1 CBSST-Peer and 1 SST-Peer group), 2 Peer Specialists will co-lead 12 groups, each lasting 20 weeks. Peer Specialists will be trained and receive an hour of supervision weekly by the CBSST developers. Master trainers from the SST rollout will train and supervise Peer Specialists in each site. All three arms' sessions will be taped and 25% rated for fidelity on standardized measures. A survey battery that assesses functioning, quality of life, recovery, and symptoms will be administered to the Veterans in each wave at: baseline, mid-intervention (10 weeks), end-of-intervention (20 weeks), and follow-up (32 weeks, 3 months post intervention). The investigators will examine all outcomes using Hierarchical Linear Models (HLM), with treatment condition included as a time-invariant covariate, and random intercepts for person and random slopes for time. Relevant covariates will include site, treatment attendance, symptom severity, service use, and demographic variables. The investigators will evaluate the effect for treatment conditions (CBSST-Peer vs. SST-Peer vs. treatment as usual group) in the expected direction and the time X group effect. Qualitative data on SST- and CBSST-Peer helpfulness and implementation factors will be collected from 8 focus groups, audio-recorded from a random sample of Veterans who participated in SST- and CBSST-Peer. Interviews will be conducted with participating Peer Specialists (n=approximately 8 per site), and key mental health staff (n=3-4 per site). The qualitative interviews and focus groups will be analyzed using rapid assessment, a team-based, iterative data collection and analysis approach providing data on the barriers and facilitators to future implementation of SST- and CBSST-Peer. Innovation: No study has tested peer-delivered SST or CBSST, or compared the two, in a rigorous trial. Significance/Expected Results: CBSST and SST are not widely available. If SST- or CBSST-Peer is effective, it could greatly increase the delivery of evidence-based services Veterans receive and enhance the services by VHA Peer Specialists.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

201 Participants Needed

Why Other Patients Applied

"I really would love to be normal. A functioning part of society. It is very hard to hold a job with this condition. I need to be steady. I do NOT like my current meds or ones I've tried before, so new therapies are of interest to me. "

EC
Bipolar Disorder PatientAge: 42

"I would like to get a medication that has fewer side effects than the ones I've used. Many antipsychotics just make me numb or flat and I can't really think. Also I like the idea of helping in research to find better medications for schizephrenia."

VT
Schizophrenia PatientAge: 60

"I’ve been treated over the years from my late teens. I’ve been through many therapists for my bipolar and my anxiety. None of it’s helped. I gave up when I was 27. It’s been 5 years of struggling day by day. My fiancé has finally suggested I look into trying to get help so I’m hoping this clinical trial will help."

WZ
Schizophrenia PatientAge: 32

"My psychosis has been manageable for the past few years since I found an antipsychotic that works okay but I still struggle with a lot of mind fog and memory issues. I haven't heard of a treatment for those symptoms until learning about new research so I'm hoping to join a trial to get access."

AQ
Schizophrenia PatientAge: 40

"I've tried lots of drugs and I still have symptoms. I'm not sure of my reality because the things I see and hear are still active. Maybe this will help one way or the other. I would be glad to help others in the future by testing a medication as well."

CY
Schizophrenia PatientAge: 62

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Schizophrenia clinical trials in West Virginia pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Schizophrenia clinical trials in West Virginia work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Schizophrenia trials in West Virginia 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in West Virginia for Schizophrenia is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in West Virginia several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Schizophrenia medical study in West Virginia?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Schizophrenia clinical trials in West Virginia?

Most recently, we added Bromocriptine for Schizophrenia and Diabetes-Related Issues, Anticholinergic Deprescription for Schizophrenia and Accelerated Transcranial Magnetic Stimulation for Schizophrenia to the Power online platform.

Why is schizophrenia more common now?

Most studies show the yearly number of new schizophrenia cases hasn’t skyrocketed; it only feels more common because doctors now catch milder cases and people with the illness live longer, so more are counted at any one time. Modern lifestyle changes—growing up in crowded cities, high-potency cannabis use, migration stress, older parenthood, and ongoing poverty—do add modest risk for certain groups, nudging overall figures upward. Recognising these drivers guides prevention efforts like early screening, substance-use education, urban social support, and good prenatal care.

What is the best injection for schizophrenia?

There isn’t one “best” injection for everyone with schizophrenia. Doctors usually choose among long-acting injectables such as paliperidone (monthly to every 6 months), aripiprazole (monthly or every 2–3 months) or risperidone (every 2 weeks to monthly) based on which oral version has helped you before, how often you can come for shots, and which side-effects you’re most sensitive to. Your psychiatrist will review these factors—plus cost, other health conditions and personal preference—to decide which LAI is the safest and most effective fit for you.

Who is most likely to recover from schizophrenia?

Research shows the best odds of meaningful recovery occur in people who get treatment quickly after their first symptoms, keep taking medication and using psychological/rehab supports, avoid alcohol or drugs, and have steady family or community support; women and those whose illness starts later in their 20s also tend to fare somewhat better, but these fixed factors matter less than the modifiable ones above. In short, while anyone with schizophrenia can improve, the combination of early intervention, sticking with care, healthy lifestyle, and strong social ties makes the biggest difference in who recovers.

Is schizophrenia inherited from mother or father?

Schizophrenia risk is passed down through many genes that you receive from both parents, and large studies do not show a consistent advantage of either the mother’s or the father’s side. Compared with the 1 % lifetime risk in the general population, the chance rises to about 10 % if one parent has schizophrenia and up to 40 % if both do; factors such as pregnancy complications, cannabis use, severe stress, or very advanced paternal age can add to that risk. Families with a history of the illness may benefit from genetic counselling and early mental-health check-ups during adolescence so any warning signs can be managed promptly.

How is schizophrenia viewed in China?

China does not have a single view of schizophrenia: in big cities many people now regard it as a treatable brain disorder, but in rural areas it may still be linked to spirit possession or seen as a source of family “shame,” so relatives often hide the illness and shoulder most care. High stigma persists because unusual behaviour is felt to threaten the family’s “face,” yet government programs such as the nationwide 686 follow-up system and the 2013 Mental-Health Law are expanding hospital care, community visits, and public education. Overall, attitudes are gradually shifting toward acceptance, but progress is uneven and support for both patients and their families remains a work in progress.

Are there any clinical trials being done for schizophrenia?

Yes—dozens of studies are actively recruiting worldwide, ranging from novel medicines like KarXT (muscarinic M1/M4 agonist), ulotaront (TAAR1 agonist), and roluperidone (aimed at negative symptoms) to long-acting weekly risperidone implants (TV-46000) and app-based cognitive programs. You can see real-time listings, eligibility criteria, and locations by typing “schizophrenia” into ClinicalTrials.gov or the EU Clinical Trials Register and then reviewing the options with your psychiatrist to weigh potential benefits, risks, and travel demands.

What is the biggest problem of schizophrenia?

Schizophrenia isn’t defined by one “biggest problem”; clinicians group its effects into positive symptoms (hallucinations/delusions), disorganization, negative symptoms (loss of drive, social withdrawal) and cognitive deficits. Studies show that after acute psychosis is controlled, the lasting obstacles to working, studying and maintaining relationships are usually the negative and cognitive symptoms, so effective care pairs antipsychotic medication with therapies and skills training that rebuild motivation, thinking and daily-living abilities.

Who has the highest rate of schizophrenia?

Worldwide, the single highest recorded rates occur in young adult Black Caribbean or Black African men who are migrants (or children of migrants) living in large urban areas; their chance of developing schizophrenia can be 4- to 9-times higher than that of white native-born residents. In general, men have a modestly higher risk than women (about 1.4 : 1), but factors such as minority or migrant status and growing up in a high-density city raise risk far more than sex alone.

What's the latest schizophrenia can develop?

Most people who develop schizophrenia do so between their late teens and early 30s, but experts recognise “late-onset” cases appearing at 40-60 and a rarer “very-late-onset schizophrenia-like psychosis” beginning after 60. Because psychosis this late in life is uncommon and can mimic problems such as dementia, stroke, or severe depression, anyone with new hallucinations or delusions at these ages should be evaluated promptly by a mental-health professional and a physician to sort out the cause and start the right treatment.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security